Obsidian Therapeutics, Inc. has reported updated Phase 1/2 data showing a 67% confirmed objective response rate with investigational amsokigene autoleucel, or amsoki-cel, in 15 patients with immune checkpoint inhibitor-resistant advanced melanoma treated at the recommended Phase 2 dose. The November 7 SITC presentation also showed median progression-free survival of 8.3 months, while median duration of response had not been reached after median study follow-up of 14.3 months.
The efficacy signal is compelling for a heavily treated melanoma population, but the size of the dataset remains its most important limitation. Ten of 15 patients responded, including two complete responses and eight partial responses, while five responses remained ongoing at the latest cut-off. One-third of all treated patients remained in deep ongoing response at 12 months after infusion.
What makes amsoki-cel particularly interesting, however, is not simply the response rate. Obsidian is attempting to redesign the practical architecture of tumour-infiltrating lymphocyte therapy by engineering the cells with pharmacologically regulatable membrane-bound interleukin-15, removing the need for systemic high-dose interleukin-2 after infusion and allowing exclusively low-dose lymphodepleting chemotherapy in the current regimen.
That could address some of the treatment burden associated with commercial TIL therapy. Whether it can do so without sacrificing efficacy or durability will depend on a much larger registration-enabling cohort that is now enrolling and is expected to produce topline data by the end of 2027.
Why does a 67% response rate attract attention in checkpoint-resistant advanced melanoma?
Patients enrolled in the amsoki-cel programme had already progressed after immune checkpoint inhibition, leaving them in a treatment setting where durable responses can become increasingly difficult to achieve. Among the 15 patients in the key efficacy population, 93% had previously received doublet checkpoint therapy and 73% had experienced disease progression after a combination of anti-PD-1 and anti-CTLA-4 treatment.
Against that background, 10 confirmed responses represent a substantial early efficacy signal. The two complete responses remained ongoing at the latest analysis, while two additional patients with partial responses had experienced complete disappearance of their measured target lesions even though they had not met all criteria required to be classified as complete responders.
Response durability is becoming increasingly relevant as follow-up lengthens. Five of the 10 responses remained ongoing after median study follow-up of 14.3 months, and five of the 15 patients treated at the recommended dose remained in deep response at the 12-month landmark. Tumour reduction in those five ranged from 72% to 100%.
Median progression-free survival reached 8.3 months, while median duration of response remained unreached. These results are encouraging but descriptive, and the confidence around any percentage derived from 15 patients remains wide. A handful of additional responses or progressions could materially change the observed rates, which is why the registration-enabling cohort rather than the SITC dataset will carry the greater regulatory weight.
How does amsoki-cel differ from conventional tumour-infiltrating lymphocyte therapy?
Tumour-infiltrating lymphocyte therapy begins with immune cells collected from a patient’s tumour. Those cells are expanded outside the body and returned to the patient after lymphodepleting chemotherapy, with the objective of providing a large population of T cells already capable of recognising tumour-associated targets.
Amsoki-cel modifies that basic approach by engineering the TIL product to express membrane-bound interleukin-15. The IL-15 activity is controlled using Obsidian’s drug-responsive technology and the established small molecule acetazolamide.
When acetazolamide is administered, it stabilises the engineered protein construct and allows membrane-bound IL-15 to appear on the T-cell surface. When the drug is absent, the engineered protein is designed to become unstable and undergo degradation. The intention is to provide a controllable growth and persistence signal rather than expose the patient continuously to an unregulated cytokine.
That engineering is important because cytokine support has historically been one of the operational challenges of TIL therapy. Conventional TIL regimens can involve high-dose systemic IL-2 after cell infusion to support expansion and persistence, contributing additional toxicity and the need for intensive monitoring.
Amsoki-cel instead uses its engineered membrane-bound IL-15 system to support the cells without systemic IL-2 administration. The mechanism has biological plausibility and translational support, but the clinical programme still needs to establish whether the approach produces consistently durable antitumour activity across a larger population.
Why is removing high-dose IL-2 potentially important for TIL therapy adoption?
The commercial benchmark for TIL therapy in melanoma is Iovance Biotherapeutics’ Amtagvi, or lifileucel, which received FDA accelerated approval in 2024 for adults with unresectable or metastatic melanoma previously treated with a PD-1 inhibitor and, where appropriate, BRAF-targeted therapy.
Amtagvi established that autologous TIL therapy can move from specialised academic experimentation into an FDA-approved commercial treatment. Its administration nevertheless remains intensive. Patients receive lymphodepleting chemotherapy before the cell infusion and can then receive intravenous high-dose aldesleukin every eight to 12 hours for up to six doses to support the infused cells.
The approved Amtagvi label contains boxed warnings covering treatment-related mortality, prolonged severe cytopenia, severe infection and cardiopulmonary and renal impairment. Treatment therefore requires specialised infrastructure and experienced multidisciplinary teams, limiting the number of centres equipped to deliver the complete regimen.
Obsidian is trying to reduce part of that burden rather than eliminate the complexity of personalised cell therapy altogether. Amsoki-cel still requires tumour procurement, individual manufacturing, lymphodepletion and infusion of an autologous cellular product. Patients also remain exposed to significant haematological toxicity associated with lymphodepleting chemotherapy.
Removing systemic IL-2 could nevertheless simplify one of the most intensive parts of the treatment sequence. If the pivotal programme confirms meaningful efficacy with an acceptable safety profile, that distinction could become clinically and operationally important.
Does amsoki-cel look better than Amtagvi based on the response rates?
It is too early to make that conclusion.
Amtagvi’s FDA efficacy analysis showed an objective response rate of 31.5% among 73 evaluable patients receiving the approved cell dose, with median duration of response not reached at the time of the regulatory analysis. Amsoki-cel has now reported a 67% response rate at the recommended Phase 2 dose, but that estimate is based on only 15 patients.
The trials were conducted separately, enrolled different patients and used different treatment regimens and follow-up periods. Differences in checkpoint exposure, baseline disease burden, patient selection, tumour procurement and other clinical factors make a direct numerical ranking unreliable.
The more appropriate interpretation is that the amsoki-cel response rate is strong enough to justify a larger registration-enabling study and potentially challenge the established commercial TIL model if it proves reproducible. It does not currently establish that amsoki-cel is more effective than lifileucel.
That distinction will become increasingly important if Obsidian reaches the market. The competitive argument would be stronger if the company can demonstrate both durable activity and a materially simpler treatment pathway rather than relying on an isolated cross-trial response-rate comparison.
Is the amsoki-cel safety profile really lighter than conventional cell therapy?
Obsidian reported no dose-limiting toxicities, treatment-related deaths, immune effector cell-associated neurotoxicity syndrome or intensive-care-unit transfers among the pooled 37 patients treated across the first-in-human and Agni-01 programmes. Only one Grade 3 cytokine release syndrome event was reported, while most common non-haematological treatment-emergent adverse events were Grade 1 or Grade 2.
Those findings are encouraging, particularly for an engineered cellular therapy, but they should not be interpreted as evidence that treatment is low risk. The peer-reviewed pooled analysis published in Nature Medicine showed that all 37 treated patients experienced at least one treatment-emergent adverse event and 89.2% experienced Grade 3 or higher events, many reflecting expected haematological consequences of lymphodepleting chemotherapy.
Serious treatment-emergent adverse events occurred in 27% of the pooled population. Reported serious non-haematological events included infections, pneumonitis, intestinal perforation, deep-vein thrombosis, dehydration and neurological or ophthalmic complications, although the presence of an event during treatment does not establish that amsoki-cel itself caused it.
The relevant safety proposition is therefore more specific than saying amsoki-cel is broadly safer. Obsidian’s regimen has so far avoided systemic IL-2, ICU transfer and several complications associated with intensive adoptive-cell therapy, while retaining the expected risks of lymphodepleting chemotherapy and complex cellular treatment. Larger patient numbers are required before uncommon toxicities or treatment-related mortality can be estimated reliably.
Can a core needle biopsy remove another barrier to commercial TIL therapy?
Traditional TIL manufacturing generally requires enough tumour tissue to isolate and expand an adequate population of tumour-infiltrating lymphocytes. Surgical tumour resection can therefore become one of the first procedural barriers patients encounter before manufacturing even begins.
Obsidian has demonstrated that amsoki-cel can also be manufactured from tissue obtained through core needle biopsy. Across the 37-patient pooled safety population, 10 patients, or 27%, had tumour material obtained by core needle biopsy while 27 underwent surgical resection.
That option could matter for patients whose tumours are difficult to remove surgically or where an additional operation creates unnecessary clinical burden. A less invasive procurement method could also make referral easier for oncology centres that do not have the surgical infrastructure traditionally associated with TIL programmes.
The evidence does not yet establish that core needle biopsy manufacturing will work for every tumour location or every patient. Tissue adequacy, tumour cellularity and manufacturing success remain important variables, while most patients in the existing dataset still underwent surgical resection.
Even so, the ability to produce responding TIL products from needle-biopsy material supports one of Obsidian’s central commercial arguments: improving accessibility may require redesigning the entire treatment workflow rather than only engineering a better cell.
How far has Obsidian moved toward a potential FDA submission?
Amsoki-cel has received both Fast Track and Regenerative Medicine Advanced Therapy designations from the FDA for immune checkpoint inhibitor-resistant unresectable or metastatic melanoma. Those designations can facilitate regulatory interaction and development but do not establish efficacy or guarantee approval.
Following discussions with the FDA, Obsidian began enrolling a registration-enabling cohort within the Phase 1/2 Agni-01 programme in August. The company is pursuing a single-arm design intended to support a future Biologics License Application under an accelerated approval strategy.
The primary endpoint is objective response rate under RECIST 1.1 assessed by blinded independent central review. Obsidian expects enrolment to be completed by the end of the first quarter of 2027 and plans to report topline results by the end of 2027.
A single-arm pathway is feasible in a setting where the regulator has already accepted objective response and response durability as a basis for accelerated approval of another TIL therapy. It still places considerable pressure on the size, durability and credibility of the observed treatment effect.
The current 15-patient cohort provides the hypothesis. The registration-enabling cohort must demonstrate that the result survives broader multicentre use, additional manufacturing runs and a substantially larger number of patients.
Why does Obsidian have enough financing to reach its pivotal melanoma readout?
Obsidian became a Nasdaq-listed company in August through a transaction with Galera Therapeutics accompanied by an oversubscribed $350 million private placement. The combined company said it had approximately $350 million in cash and cash equivalents following the transaction and expected those resources to fund operations into the second half of 2028.
That runway extends beyond two major planned clinical catalysts. Obsidian expects initial Phase 1 data from amsoki-cel in non-small cell lung cancer during the first half of 2027, followed by topline results from the melanoma registration-enabling cohort by year-end 2027.
Financing is particularly important in autologous cell therapy because clinical development is only part of the capital requirement. A company approaching commercialisation must establish reproducible manufacturing, logistics, quality systems, treatment-centre support and capacity for a patient-specific product.
The $350 million financing therefore reduces near-term funding pressure but does not remove the execution challenge. If registration-enabling results are positive, Obsidian will need to demonstrate that its manufacturing process can support regulatory inspection and eventually commercial demand without losing the product consistency seen in clinical trials.
What does the 44% Obsidian share-price jump say about investor expectations?
Obsidian shares closed around $13.87 on November 6, up approximately 44% from the previous session after the updated amsoki-cel data were released. Trading volume increased sharply to about 2.1 million shares.
The move followed an unusually difficult stretch for the recently listed biotechnology company. Shares had fallen from $14.79 on October 30 to $9.60 on November 5 before rebounding after the SITC update, meaning the one-day surge recovered much of the preceding week’s decline rather than creating an uninterrupted new high.
The stock also remained far below the levels reached shortly after the company began trading under the OBX ticker in August. That broader context suggests investors are still placing a substantial discount on the clinical and regulatory risk surrounding a programme whose principal efficacy evidence comes from a very small population.
The November reaction nevertheless shows the value the market places on durable responses and a potentially differentiated TIL treatment model. For a company whose valuation remains dominated by one lead clinical programme, every additional month of response durability can materially change expectations.
Could amsoki-cel turn TIL therapy into a broader solid-tumour platform?
Obsidian is already testing that proposition in non-small cell lung cancer within Agni-01, with initial Phase 1 results expected during the first half of 2027. Lung cancer represents a much larger commercial opportunity than checkpoint-resistant melanoma, but it is also a more demanding biological setting for cellular therapy.
The company’s cytoDRiVE platform is intended to provide broader control over protein activity inside engineered cells using small molecules. If membrane-bound IL-15 proves clinically useful, the technology could potentially be applied to other cellular programmes where persistence, activation and toxicity need to be balanced.
A single successful melanoma programme would not validate the entire platform. TIL biology differs across tumour types, and sufficient tumour-reactive lymphocytes may be easier to generate in some cancers than others. The NSCLC cohort therefore provides an important early test of whether the engineering strategy travels beyond melanoma.
For now, the melanoma programme remains the decisive asset. Its significance comes from combining two separate propositions: potentially strong antitumour activity and a treatment regimen designed to remove some of the operational burdens that limit existing TIL therapy.
What must happen before amsoki-cel can genuinely challenge the commercial TIL model?
The next dataset needs to do more than reproduce a headline response rate. Obsidian must show that responses remain durable as follow-up matures, that the treatment effect persists across more centres and manufacturing batches, and that the safety profile remains manageable when considerably more patients receive the regimen.
Manufacturing success will be equally important. Autologous cell therapy depends on successfully converting an individual patient’s tumour sample into a releasable product within a clinically practical timeframe. Any meaningful rate of manufacturing failure, prolonged turnaround or inconsistent potency could weaken the accessibility advantage created by needle biopsy and an IL-2-free regimen.
Treatment-centre experience will also determine how much of the theoretical workflow advantage becomes real. Low-dose lymphodepletion may be compatible with outpatient administration, but that does not mean every patient will avoid hospitalisation or specialist monitoring. Cell therapy remains medically and logistically complex even when one component of the regimen is simplified.
Obsidian has nevertheless reached an important inflection point. Amsoki-cel has produced confirmed responses in two-thirds of the small recommended-dose cohort, five patients remained in deep response at one year, median duration of response has not yet been reached, and the regimen has avoided systemic IL-2.
Those findings are sufficient to make the programme one of the more interesting attempts to build a second generation of TIL therapy after Amtagvi established that the modality can reach commercial medicine. They are not sufficient to establish that Obsidian has already built a better TIL.
That answer now rests with the registration-enabling Agni-01 cohort. If a substantially larger multicentre population preserves both the response depth and the lower-burden treatment model, amsoki-cel could compete on something more durable than an impressive Phase 1/2 percentage: making personalised TIL therapy easier for cancer centres to deliver and for patients to undergo.
